Research confirms value of risk-reducing salpingo-oophorectomy for women with BRCA mutations
Another outbreak of bird flu has hit Vietnam this time affecting the north of the country. This latest outbreak has resurfaced in poultry in northern Vietnam and killed ducks and chickens at two farms following a number of months without any new cases of the deadly H5N1 virus. According to reports the outbreak occurred
Full Post: Bird flu returns again to Vietnam
Prophylactic salpingo-oophorectomy-removal of the ovaries and fallopian tubes–reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the Journal of the National Cancer Institute.
Previous studies have shown substantial reduction in the risks of breast and ovarian or fallopian tube cancers in BRCA1/2 mutation carriers following salpingo-oophorectomy. However, the magnitude of the benefit has been unclear.
To establish a more reliable estimate of the magnitude of the benefit, Timothy Rebbeck, Ph.D., of the University of Pennsylvania School of Medicine in Philadelphia, and colleagues analyzed the pooled results of 10 published studies.
They found that risk-reducing salpingo-oophorectomy was associated with a 79 percent relative reduction in ovarian and fallopian tube cancer risk and a 51 percent relative reduction in breast cancer risk in women who carried mutations in BRCA 1 or BRCA2 . When the researchers analyzed the effect of the prophylactic surgery on BRCA1 and BRCA2 mutation carriers separately, they found a similar benefit for the two groups in terms of breast cancer risk, with a 53 percent risk reduction for each group. The groups were too small to be examined independently for gynecologic cancer risk.
“In conclusion, the summary risk reduction estimates presented here confirm that BRCA1/2 mutation carriers who have been treated with [risk-reducing salpingo-oophorectomy] have a substantially reduced risk of both breast and ovarian cancer,” the authors write. “However, residual cancer risk remains after surgery. Therefore, additional cancer risk reduction and screening strategies are required to maximally reduce cancer incidence and mortality in this high-risk population.”
In an accompanying editorial, Mark H. Greene, M.D., and Phuong L. Mai, M.D., of the National Cancer Institute in Bethesda, Md., commend Rebbeck and colleagues’ effort and review the steps the study authors took to develop the most precise estimates of risk reduction following prophylactic salpingo-oophorectomy. The results “should benefit women who are trying to decide whether or not to undergo [risk-reducing salpingo-oophorectomy],” the editorialists write. “We urge providers of cancer genetics counseling services to adopt the summary risk estimates developed by Rebbeck et al. as those most currently reliable when counseling BRCA mutation carriers.”
Women who have a strong family history of breast cancer are over four times more likely to develop the disease than the general population, according to research published in the British Journal of Cancer. This is the first time the risk for women who do not have a faulty BRCA gene but have one first-degree
Full Post: Breast cancer four times more likely in women with strong family history
A baby girl about to be born in Britain will be the first to have been screened for a breast cancer causing gene. The baby’s mother, is due to give birth soon to the first British baby to have been screened to be free of a gene which can cause breast cancer. The baby’s parents
Full Post: Baby girl due soon will be minus breast cancer causing gene
Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women. Sporadic breast cancer, which is non-hereditary, turns out to be the most widespread, representing 85 to 90% of all cases, but remains the least well-known. Researchers at CNRS and CEA, working with a team from H?al
Full Post: Does hormone treatment predispose patients to breast cancer?
Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review published December 9 in the Journal of the National Cancer Institute. Numerous regimens have been tested in advanced breast cancer. However, each
Full Post: Nonhormonal treatment regimens improve survival in patients with metastatic breast cancer
The power of the drug tamoxifen to reduce breast density is key in preventing breast cancer - according to a presentation in America by Cancer Research UK scientists. Researchers monitored the extent to which tamoxifen could reduce breast density in 7000 healthy post menopausal women who are at high risk of breast cancer in a
Full Post: How tamoxifen prevents breast cancer in some women but not others